Tagged: series-a
30 results
NEOK Bio
NEOK Bio is a Palo Alto-based clinical-stage biotechnology company developing bispecific antibody drug conjugates (ADCs) for solid tumors. Founded and led by physician-executive Mayank Gandhi and backed by Korean antibody specialist ABL Bio, NEOK launched from stealth in November 2025 with a $75 million Series A. Its dual-targeting approach binds two complementary tumor antigens at once, aiming to widen the therapeutic window and overcome the resistance and toxicity limits of conventional single-target ADCs. The company's two lead programs, NEOK001 (ROR1/B7-H3) and NEOK002 (EGFR/MUC1), both cleared FDA IND review in early 2026 and are headed into Phase 1 studies.
Redrob
Redrob is an AI company building large language models and go-to-market tools for sales, recruitment, and prospecting. Its platform combines a 700M+ contact data pool, verified emails, and real-time buying signals to help B2B teams find prospects, automate outreach, and screen talent. Founded by former international lawyer Felix Kim, Redrob positions itself as an affordable, enterprise-grade AI stack for emerging markets and cost-conscious companies, and aims to become one of the world's most-used LLM platforms by 2028.
Marlon Misra
Marlon Misra is the cofounder and CEO of Assembly (formerly Copilot), a Y Combinator-backed New York software company building a client-portal platform - often described as 'Shopify for service businesses.' Assembly raised a $10M Series A, serves more than 1,000 firms and roughly a million of their clients, and rebranded from Copilot in September 2025 alongside the launch of an AI assistant for professional services firms.
Matt Kennedy
Matt Kennedy is co-founder and CEO of Mantra Health, a New York-based digital mental health company that partners with over 150 college and university campuses to deliver telepsychiatry, teletherapy and campus-wide wellness programs to more than 1.3 million students. He moved from COO to CEO in 2023, and leads a team of roughly 130 employees and 100+ in-house clinicians.
Mehul Bhatt
Mehul Bhatt is co-founder and CEO of FloCareer, an interview-as-a-service HR tech platform that dispatches expert freelance interviewers (plus AI proctoring) to run structured technical screens for enterprises. A former Cisco solutions architect with a Master's from Illinois Institute of Technology, he spent 16 years as an individual contributor before starting the company with Mohit Jain. FloCareer raised a $5.7M Series A in October 2021 and has conducted more than one million interviews for 600+ clients across the US and India.
Mike Shebat
Mike Shebat is the co-founder and CEO of Traba, a New York-based labor marketplace that supplies vetted on-demand workers to warehouses, distribution centers, and light industrial employers. He started the company in 2021 after seeing, from inside a McMaster-Carr shipping floor and later Uber Eats, how often temp workers simply don't show up. Traba has raised roughly $46 million from Founders Fund and Khosla Ventures, and Shebat, a Forbes 30 Under 30 honoree, runs it on a famously intense in-office schedule.
Patrick Anderson
Patrick Anderson is Co-Founder and CTO of Moab, a New York based startup building a modern operating system for equipment rental and dealership businesses. He was previously Head of Core Engineering at Ramp, joining the fintech as its 11th employee. In February 2026 Moab emerged from stealth with $16M in combined Seed and Series A funding backed by Elad Gil and Ironspring Ventures.
Rob Hayden
Rob Hayden is the CEO and co-founder of Renew, a New York based AI powered retention platform for multifamily and single family rental operators. He co-founded the company in 2021 with Kevin Murphy after both worked together at rental insurance startup Jetty. In October 2025 Renew closed a $12 million Series A led by Haymaker Ventures with participation from Goldcrest Capital and Upfront Ventures, bringing total funding to roughly $20 million and financing the launch of the industry's first Resident Referral Network.
Robert Brennan
Robert Brennan is co-founder and CEO of All Hands AI, the company behind OpenHands, an MIT-licensed open source platform for AI coding agents that started life in 2024 as an OpenDevin fork built in 24 hours after Cognition's Devin demo. A former Google search engineer who patented an answer-extraction algorithm shipped inside Google Search in 2013, Brennan later founded DataFire and led open source at Fairwinds before helping launch OpenHands with Xingyao Wang and Graham Neubig. The company has raised roughly $23.8M total across a $5M Menlo-led seed and an $18.8M Series A led by Madrona in November 2025.
Romaric Philogène
Romaric Philogène is the CEO and co-founder of Qovery, a platform-engineering company that turns cloud infrastructure into a self-service experience for developers. A former site reliability engineer with a decade in ad-tech and financial systems, he started Qovery in 2019 with Pierre Mavro and Morgan Perry and, in September 2025, raised a $13M Series A led by IRIS and Crane Venture Partners, with angel checks from Datadog's Olivier Pomel and Alexis Lê-Quôc.
Stefan Bauer
Stefan Bauer is the co-founder and CEO of Marker Learning, a New York City telehealth company that connects families and schools with licensed psychologists for learning disability evaluations, cutting the traditional cost and turnaround time of assessments. A Yale School of Management MBA and former McKinsey and Morgan Stanley professional, Bauer co-founded the company with Emily Yudofsky in 2021; it has since raised $19.7 million in total funding, including a $15 million Series A led by Andreessen Horowitz in 2023.
Applied Carbon
Applied Carbon (formerly Climate Robotics) builds tractor-pulled machines that turn crop residue into biochar in a single pass across the field. The Houston-based startup converts post-harvest plant waste into a stable form of carbon that improves soil health and locks CO2 underground for centuries, selling carbon removal credits to buyers including Microsoft.
Fulcrum
Fulcrum is a San Francisco AI platform that automates the unglamorous backbone of insurance brokerages - policy checking, proposal generation, certificate issuance and carrier sales prep - so account managers can scale their books of business without scaling headcount. Founded in 2023 by Arjun Mangla and Sambhav Anand, it raised $25M in combined Seed and Series A led by CRV in January 2026 and is in use at nearly half of the top 50 U.S. brokerages.
Impart Security
Impart Security is a San Francisco cybersecurity company building a unified runtime protection platform for AI, APIs, and web applications. Founded in 2020 by Signal Sciences veterans Jonathan DiVincenzo, Marc Harrison, and Brian Joe, the company merges WAF, API security, Cloud Application Detection & Response, and AI Runtime Protection into one engine that runs autonomous defense agents inside production traffic.
Kimia Therapeutics
Kimia Therapeutics is a Berkeley-based biotech building ATLAS, a drug-discovery platform that pairs nanoliter-scale high-throughput precision chemistry with machine learning and genome editing to map the druggable space at single-atom resolution. Spun out of Carmot Therapeutics in 2023 and backed by $55M in Series A funding, Kimia is using its chemical atlas to advance therapeutic programs in cancer and immunology.
Kolena
Kolena is a San Francisco-based AI company building software that automates document-heavy workflows for regulated industries - real estate, insurance, banking, and financial services. Founded in 2021 by Mohamed Elgendy, Andrew Shi, and Gordon Hart, the company began as a rigorous ML model testing platform and has since extended that quality-first DNA into agentic document workflow automation, with an emphasis on transparency, citations, and auditability.
Mandolin
Mandolin is a San Francisco healthcare AI company building agents that handle the paperwork blocking patients from specialty drugs. Its software automates intake, benefits verification, prior authorization, and claims work for infusion providers, specialty pharmacies, and health systems - the back office that decides how quickly a cancer or Alzheimer's patient actually gets treated.
Paxton AI
Paxton AI is an all-in-one generative AI assistant built for lawyers. It handles legal research, document drafting, contract review, and mass document analysis across U.S. federal and state law, with a published 94% non-hallucination rate benchmarked against Stanford research. Founded in 2023 by Tanguy Chau and Michael Ulin, the company is based in Palo Alto and has raised $28M total, including a $22M Series A led by Unusual Ventures in January 2025.
Cajal Therapeutics
Cajal Therapeutics (originally launched as Cajal Neuroscience) is a Seattle biotechnology company developing novel medicines to restore biological homeostasis, with a focus on neurodegenerative diseases, anemias of inflammation, and iron-related disorders. Built on a platform that pairs integrative human genetics, high-throughput functional genomics, and industrialized whole-brain imaging with deep neuroscience expertise, the company aims to systematically validate disease targets at unprecedented scale and translate them into small molecule and RNA therapeutics. It launched in November 2022 with a $96 million Series A and counts a roster of celebrated neuroscientists among its co-founders.
Delphia Therapeutics
Delphia Therapeutics is a Cambridge, Massachusetts biotech pioneering a new field of cancer biology it calls activation lethality - the idea that cancer cells with oncogenic mutations live dangerously close to the upper limit of how much pathway activity they can tolerate, and can be pushed past it. Rather than blocking cancer signals like most drugs, Delphia designs targeted activators that overload cancer's stress pathways until the cell dies, aiming for durable benefit and a way around drug resistance. Founded in 2024 by Kevin Marks, Bill Sellers and Mike Dillon, it launched with a $67 million Series A led by GV, Nextech Invest, Polaris Innovation Fund and Alexandria Venture Investments.
Immetas Therapeutics
Immetas Therapeutics is a New Jersey biotech building drugs that target the chronic, low-grade inflammation that drives aging and age-related disease - what scientists call 'inflammaging.' Founded in 2018 by drug-development veteran J. Gene Wang and Harvard aging researcher David Sinclair, the company designs bispecific antibodies and other biologics to reprogram the innate immune system, aiming to treat age-related cancers and inflammatory and autoimmune disease. It raised an $11M Series A from Morningside Ventures in 2020 and partners with GC Biopharma on mRNA therapeutics.
Nilo Therapeutics
Nilo Therapeutics is a New York-based biotechnology company developing a new class of medicines that target the brain-body neural circuits regulating the immune system. Building on discoveries that identified specific vagal neurons controlling systemic inflammation, Nilo aims to restore immune homeostasis centrally rather than broadly suppress the immune system, offering a differentiated approach to treating autoimmune and inflammatory disease. The company launched out of stealth in October 2025 with a $101 million Series A.
Ollin Biosciences
Ollin Biosciences is an Austin-based clinical-stage biopharmaceutical company building a portfolio of best-in-disease therapies for vision-threatening eye diseases. Founded in 2023 and launched publicly in September 2025 with $100M in Series A financing, Ollin in-licenses validated drug candidates and races them through head-to-head trials against the market leaders. Its lead program, OLN324, is a VEGF/Ang2 bispecific antibody for wet age-related macular degeneration and diabetic macular edema that posted superior anatomic results versus Roche's blockbuster Vabysmo in a Phase 1b study.
Treeline Biosciences
Treeline Biosciences is a Watertown, Massachusetts biotech founded in 2021 by Loxo Oncology founder Josh Bilenker and former Novartis oncology head Jeff Engelman. It pairs in-house wet-lab R&D with leading-edge computational tools to invent cancer medicines reliably and repeatedly, choosing targets by what the technology can reach rather than by therapeutic fashion. After operating largely in stealth, Treeline has raised more than $1.1 billion and moved three programs - a BCL6 degrader, a pan-KRAS inhibitor, and an EZH2 inhibitor - into Phase 1 trials. In June 2026 it agreed to go public through an all-stock reverse merger with Standard BioTools, with the combined company set to trade on Nasdaq as 'TRLN'.
Zag Bio
Zag Bio is a Cambridge, Massachusetts biotechnology startup pioneering thymus-targeted medicines for autoimmune disease. Founded and incubated by Polaris Partners and launched in October 2025 with an $80M Series A, the company designs bifunctional antibodies that ferry self-antigens directly into the thymus - the organ that trains immune cells - to re-teach the body to tolerate its own tissue rather than attack it. Its lead program, ZAG-101, aims to prevent or delay Type 1 diabetes by inducing durable, antigen-specific central tolerance instead of broad immunosuppression.
one.bio
one.bio is a Sacramento biotechnology company that releases short-chain plant fibers and makes them flavorless, odorless, colorless and water-soluble so they can be added to food and drinks at high doses without changing taste or texture. Spun out of UC Davis, it pairs a fiber-mapping knowledgebase called the Glycopedia with a proprietary depolymerization process to turn long-chain plant carbohydrates - including agricultural byproducts - into bioactive fibers that feed the microbiome and support metabolic and immune health. The company raised a $27M Series A in December 2024 and in early 2026 launched its discovery platform, its first clinically validated ingredient (one.bio 01) and a consumer brand, GoodVice.
Paul Singer
Paul Singer is the cofounder and CEO of FleetWorks, a San Francisco startup building always-on voice AI agents that handle the phone-and-email grind of freight brokerage. A former Uber Freight product manager and Yale economics grad, he started FleetWorks in late 2022 with cofounder Quang Tran, went through Y Combinator's Summer 2023 batch, and in October 2025 raised a $17M round (including a $15M Series A led by First Round Capital) to automate the matching of trucks with cargo across a $1T+ industry.
Calluna Pharma
Calluna Pharma is an Oslo-based clinical-stage biotech building first-in-class antibodies that switch off the upstream signals driving inflammation and fibrosis. Formed in 2024 from the merger of Oxitope Pharma and Arxx Therapeutics and backed by a EUR 75 million Series A, the company targets damage-associated molecular patterns (DAMPs) such as S100A4 to halt diseases like idiopathic pulmonary fibrosis at their root rather than managing symptoms.
dub
dub is America's first regulated copy-trading platform, letting everyday investors mirror the portfolios of top traders, hedge-fund managers, and even politicians with a single tap. Founded by 23-year-old Harvard dropout Steven Wang and headquartered in New York, the SEC-registered, FINRA-member, SIPC-insured app has surpassed 1 million downloads and raised $47M total, including a $30M Series A in May 2025 co-led by Notable Capital and Neo.
Hinge Bio
Hinge Bio is a clinical-stage biotechnology company in Burlingame, California, building next-generation antibody therapeutics on its proprietary GEM-DIMER platform. The platform engineers multivalent, multispecific antibodies that bind their targets cooperatively for dramatically enhanced potency. Its lead candidate, HB2198, is a B cell-depleting agent targeting both CD19 and CD20 with enhanced natural killer cell engagement, now in Phase 1 trials for systemic lupus erythematosus and lupus nephritis. The company raised a $30M Series A led by Point72 in January 2025.